Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

OncoSec Medical

  • Dan O'Connor, OncoSec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy platform – TAVO™ enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAV

  • Date:Monday, February 11
  • Time:9:00 AM - 9:15 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23642
  • Company HQ Zip:92121
  • Goal for Presentation:Visibility
  • Company Website:https://oncosec.com/
  • Company HQ City:San Diego
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:ONCS
  • Exchange:Nasdaq
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:TAVO + pembrolizumab
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:We would like to present at 9am on Monday the 11th
Speakers
Dan O'Connor
OncoSec
Back